Johnson & Johnson (J&J) is reportedly considering to buy biotechnology company Ollin Biosciences in a deal worth up to $3.4 billion. The proposed Johnson & Johnson acquisition of Ollin Biosciences could strengthen the pharmaceutical company’s presence in retinal disease treatment through OLN324, an experimental drug candidate targeting two major causes of vision loss.
According to a Financial Times report, the proposed Ollin Biosciences acquisition deal includes $2.2 billion in upfront cash and up to $1.2 billion in additional milestone payments. However, discussions could still fall through, and neither company has confirmed the transaction yet.
What Is Ollin Biosciences’ Experimental Retinal Disease Treatment?
The proposed Johnson & Johnson acquisition of Ollin Biosciences would give the pharma giant access to OLN324, Ollin Biosciences’ lead experimental drug candidate. Ollin is developing the medicine for two retinal conditions that can cause severe vision impairment. OLN324 is expected to enter Phase 3 clinical trials.
- Wet Age-Related Macular Degeneration (AMD)
Wet AMD is an advanced form of age-related eye disease in which abnormal blood vessels grow beneath the retina, the light-sensitive tissue at the back of the eye. These vessels can leak fluid or blood, damaging central vision.
- Diabetic Macular Edema (DME)
DME develops when diabetes damages blood vessels in the retina, allowing fluid to accumulate in the macula, the area responsible for sharp central vision. The condition can cause blurred vision and serious visual impairment.
Who Funded The Clinical Developments of Ollin’s Drug?
Ollin Biosciences raised $330 million in June 2026 to support the upcoming late-stage studies of OLN324. Its investors include Arch Venture Partners, Mubadala Capital, TCGX, RA Capital and Monograph Capital.
This funding supports the development of its experimental retinal medicine and adds to the company’s appeal as a potential acquisition target.
Why Is J&J Expanding Into the Retinal Therapeutics Market?
The potential Johnson & Johnson acquisition of Ollin Biosciences would help J&J establish a stronger position in retinal disease medicines, an area where the company has a relatively limited presence despite its established contact lens business.
The retinal therapeutics market has attracted investment from several major pharmaceutical companies. Merck and Bayer have also pursued opportunities in eye disease drug development through biotechnology acquisitions. Meanwhile, Regeneron’s Eylea has become one of the leading blockbuster medicines for retinal diseases.
Access to OLN324 after the Ollin Biosciences acquisition could therefore provide J&J with an opportunity to expand its pharmaceutical pipeline into a specialized treatment area.
What’s Next in the J&J And Ollin Biosciences Deal?
The Financial Times reported that the Johnson & Johnson Acquisition of Ollin Biosciences could be announced as early as November 16, 2026. However, negotiations remain subject to change, and the companies have not confirmed a completed transaction in the available reporting.
The final deal terms and OLN324’s progress into Phase 3 clinical trials will be important developments to watch.










